Psoriasis Series

Biosimilars: Where Are We Now?


Lectures: 0
Credits: 0.75
Supported by independent educational grants from Ortho Dermatologics and Sun Pharmaceutical Industries, Inc.

About this course

Skill level: intermediate
Estimated time to complete activity: 45 min
Release date: October 08, 2018
Expiration date: October 07, 2019


American Nurses Credentialing Center(ANCC), American Medical Association(AMA)


This activity is part of a 14-course series designed to equip licensed practitioners from medical, nursing, and related disciplines with a multidisciplinary approach to managing patients with psoriasis.

13. Biosimilars: Where Are We Now?

Biosimilar medications are "highly similar" to an already FDA-approved biological product. Several biosimilars have already been approved in the US for the treatment of psoriasis, with more sure to follow in the near future. The FDA is responsible for and has a process for ensuring the safety and efficacy of biosimilars.

Educational Objectives

After completing this activity, participants will able to:

  • Review the difference between a biosimilar and a generic drug
  • Outline the FDA requirements for approval of a biosimilar
  • Discuss the special safety and efficacy issues of biosimilars

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Faculty Reported Financial Relationship
Paul Yamauchi, MD, PhD

Consultant/Speaker/Principlal Investigator: AbbVie, Amgen, Celgene Corporation, Dermira, Galderma USAJanssen-Orth Inc., LEO Pharma, US, Lilly ICOS LLC, Medimmune, Menlo Therapeutics, Novartis Pharmaceuticals Corp., Ortho Dermatologics, Pfizer Inc., Regneron, Sun Pharmaceutical Industries Ltd.

Advisory Board: Amgen, Dermira, Lilly ICOS LLC

Contact Information

This activity is jointly provided by SynAptiv and Dermeda

Questions about CE accreditation or CE certificates related to this course, please contact us via email at

Copyright © 2018 Dermveda. All rights reserved. This material may not be reproduced, displayed, modified or distributed without the express prior written permission of the copyright holder.


Lectures: 0
Credits: 0.75